Granulocyte Colony-Stimulating Factor for Treatment of Patients with Chronic Traumatic Brain Injury: A Preliminary Pre-Post Study

Chronic traumatic brain injury (TBI) can cause permanent disability and thereby negatively affect patients, families, and society. Currently, there is no effective treatment for patients with chronic TBI. One possible option is granulocyte colony-stimulating factor (G-CSF), which has potential neuro...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Tsung-Lang Chiu, Ya-Jung Wang, Tze-Wei Chang, Shinn-Zong Lin, Sheng-Tzung Tsai
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	G-CSF traumatic brain injury outcome Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571
Acceso en línea:	https://doaj.org/article/6c405b86a60d46c796331d0a76c8a41e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6c405b86a60d46c796331d0a76c8a41e
record_format	dspace
spelling	oai:doaj.org-article:6c405b86a60d46c796331d0a76c8a41e2021-11-25T16:57:29ZGranulocyte Colony-Stimulating Factor for Treatment of Patients with Chronic Traumatic Brain Injury: A Preliminary Pre-Post Study10.3390/brainsci111114412076-3425https://doaj.org/article/6c405b86a60d46c796331d0a76c8a41e2021-10-01T00:00:00Zhttps://www.mdpi.com/2076-3425/11/11/1441https://doaj.org/toc/2076-3425Chronic traumatic brain injury (TBI) can cause permanent disability and thereby negatively affect patients, families, and society. Currently, there is no effective treatment for patients with chronic TBI. One possible option is granulocyte colony-stimulating factor (G-CSF), which has potential neuroregenerative and neuroprotective effects through its ability to mobilize hematopoietic stem cells and increase neurogenic growth factor levels. Previous studies have shown that G-CSF administration is safe for patients with neurological diseases such as stroke and dementia. The present study aimed to explore the safety and efficacy of G-CSF use in patients with chronic TBI. Methods: 38 patients with chronic TBI were administered 3-day rounds of G-CSF (10 μg/kg per day) once a month for 6 months. These patients were clinically evaluated using the modified Rankin scale (mRS) and Karnofsky Performance Score (KPS). Laboratory measures of the leucocyte counts and differential count percentage were also assessed. Results: At the 6-month follow-up, further assessment showed that patients tolerated the treatment well with only mild and transient side effects being observed. Further clinical evaluation showed significant improvements in mRS and KPS after G-CSF treatment. Laboratory results also confirmed the action of the medication, with increased leukocytosis and band forms. Conclusions: The results suggest that 6-month chronic G-CSF treatment is safe for patients with chronic TBI and may provide clinical benefits and neurological improvements. The adverse effects of the treatment, however, are transient and usually tolerable. Thus, these preliminary findings suggest that future clinical trials of G-CSF use in patients with chronic TBI are warranted.Tsung-Lang ChiuYa-Jung WangTze-Wei ChangShinn-Zong LinSheng-Tzung TsaiMDPI AGarticleG-CSFtraumatic brain injuryoutcomeNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571ENBrain Sciences, Vol 11, Iss 1441, p 1441 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	G-CSF traumatic brain injury outcome Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571
spellingShingle	G-CSF traumatic brain injury outcome Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Tsung-Lang Chiu Ya-Jung Wang Tze-Wei Chang Shinn-Zong Lin Sheng-Tzung Tsai Granulocyte Colony-Stimulating Factor for Treatment of Patients with Chronic Traumatic Brain Injury: A Preliminary Pre-Post Study
description	Chronic traumatic brain injury (TBI) can cause permanent disability and thereby negatively affect patients, families, and society. Currently, there is no effective treatment for patients with chronic TBI. One possible option is granulocyte colony-stimulating factor (G-CSF), which has potential neuroregenerative and neuroprotective effects through its ability to mobilize hematopoietic stem cells and increase neurogenic growth factor levels. Previous studies have shown that G-CSF administration is safe for patients with neurological diseases such as stroke and dementia. The present study aimed to explore the safety and efficacy of G-CSF use in patients with chronic TBI. Methods: 38 patients with chronic TBI were administered 3-day rounds of G-CSF (10 μg/kg per day) once a month for 6 months. These patients were clinically evaluated using the modified Rankin scale (mRS) and Karnofsky Performance Score (KPS). Laboratory measures of the leucocyte counts and differential count percentage were also assessed. Results: At the 6-month follow-up, further assessment showed that patients tolerated the treatment well with only mild and transient side effects being observed. Further clinical evaluation showed significant improvements in mRS and KPS after G-CSF treatment. Laboratory results also confirmed the action of the medication, with increased leukocytosis and band forms. Conclusions: The results suggest that 6-month chronic G-CSF treatment is safe for patients with chronic TBI and may provide clinical benefits and neurological improvements. The adverse effects of the treatment, however, are transient and usually tolerable. Thus, these preliminary findings suggest that future clinical trials of G-CSF use in patients with chronic TBI are warranted.
format	article
author	Tsung-Lang Chiu Ya-Jung Wang Tze-Wei Chang Shinn-Zong Lin Sheng-Tzung Tsai
author_facet	Tsung-Lang Chiu Ya-Jung Wang Tze-Wei Chang Shinn-Zong Lin Sheng-Tzung Tsai
author_sort	Tsung-Lang Chiu
title	Granulocyte Colony-Stimulating Factor for Treatment of Patients with Chronic Traumatic Brain Injury: A Preliminary Pre-Post Study
title_short	Granulocyte Colony-Stimulating Factor for Treatment of Patients with Chronic Traumatic Brain Injury: A Preliminary Pre-Post Study
title_full	Granulocyte Colony-Stimulating Factor for Treatment of Patients with Chronic Traumatic Brain Injury: A Preliminary Pre-Post Study
title_fullStr	Granulocyte Colony-Stimulating Factor for Treatment of Patients with Chronic Traumatic Brain Injury: A Preliminary Pre-Post Study
title_full_unstemmed	Granulocyte Colony-Stimulating Factor for Treatment of Patients with Chronic Traumatic Brain Injury: A Preliminary Pre-Post Study
title_sort	granulocyte colony-stimulating factor for treatment of patients with chronic traumatic brain injury: a preliminary pre-post study
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/6c405b86a60d46c796331d0a76c8a41e
work_keys_str_mv	AT tsunglangchiu granulocytecolonystimulatingfactorfortreatmentofpatientswithchronictraumaticbraininjuryapreliminaryprepoststudy AT yajungwang granulocytecolonystimulatingfactorfortreatmentofpatientswithchronictraumaticbraininjuryapreliminaryprepoststudy AT tzeweichang granulocytecolonystimulatingfactorfortreatmentofpatientswithchronictraumaticbraininjuryapreliminaryprepoststudy AT shinnzonglin granulocytecolonystimulatingfactorfortreatmentofpatientswithchronictraumaticbraininjuryapreliminaryprepoststudy AT shengtzungtsai granulocytecolonystimulatingfactorfortreatmentofpatientswithchronictraumaticbraininjuryapreliminaryprepoststudy
_version_	1718412841760849920

Granulocyte Colony-Stimulating Factor for Treatment of Patients with Chronic Traumatic Brain Injury: A Preliminary Pre-Post Study

Ejemplares similares